Royalty Transparency Act
- Bill Number
- S. 855
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Government Operations and Politics
- Status
- Introduced
- Latest Action
- 2025-09-17: Placed on Senate Legislative Calendar under General Orders. Calendar No. 165.
- Last Updated
- 2025-12-05T21:31:58Z
AI-Generated Summary
Purpose of the Legislation
The Royalty Transparency Act (S. 855) aims to promote transparency and prevent conflicts of interest by requiring executive branch employees, particularly those in scientific and public health advisory roles, to disclose royalties they receive from inventions developed during their government work. This ensures public accountability while maintaining protections for sensitive information.
Key Provisions
- Expanded Financial Disclosure Requirements:
- Amends Section 13103 of Title 5, U.S. Code, to require members of specific advisory committees (e.g., National Science Advisory Board for Biosecurity, Advisory Committee on Immunization Practices, and others focused on vaccines, biosecurity, and science) to file public financial disclosure reports.
- Directs the Government Accountability Office (GAO) to annually identify additional advisory committees that influence public health policy and have had implemented recommendations in the past 10 years; these committees' members must also file disclosures (this provision sunsets after 5 years).
- Mandates disclosure of the source and value of royalties from government-related inventions, including payments under the Federal Technology Transfer Act of 1986, for the employee, spouse, or dependent child.
- Waiver Notifications:
- Updates Sections 13103(i) of Title 5 and 208 of Title 18, U.S. Code, to require supervising ethics offices to notify congressional committees (e.g., Homeland Security and Governmental Affairs, Oversight and Government Reform) of any waivers granted for disclosure requirements, including detailed justifications.
- Public Access and Reporting:
- Amends Section 13104(a) of Title 5 to include royalty details in public reports, overriding prior exemptions in the Stevenson-Wydler Technology Innovation Act and patent laws.
- Requires agencies to publish these reports online and provide unredacted copies (except for personal identifiers like Social Security numbers or home addresses) to Members of Congress within 30 days of a request.
- For confidential filers (under Section 13109 of Title 5), adds royalty disclosure requirements and similar congressional access rules.
- Agencies must submit annual reports to Congress on confidential disclosures, including filer counts and reasons for confidentiality; intelligence agencies report to intelligence committees.
- Agencies must annually publish lists of employees who report royalties, including names, sources, and values.
- Conflict of Interest in Acquisitions (Section 3):
- Directs the Federal Acquisition Regulatory Council and Office of Management and Budget to update regulations so conflict reviews for contractors and grantees include scrutiny of royalties paid in the prior year.
- Agencies must annually report to Congress on identified royalty-related conflicts and mitigation steps.
- Severability (Section 4):
- Ensures that if any part of the Act is ruled unconstitutional, the rest remains in effect.
Significant Changes to Existing Law
- Overrides Confidentiality Exemptions: Removes protections under the Stevenson-Wydler Act (15 U.S.C. 3710a) and patent laws (35 U.S.C. 209) that previously shielded royalty details from public disclosure for government inventors.
- Broadens Filing Obligations: Adds new categories of advisory committee members to public disclosure requirements (previously limited), with a temporary GAO expansion mechanism.
- Enhances Oversight: Introduces mandatory congressional notifications for waivers, public online publication of reports, and annual agency reporting on disclosures and conflicts—features not previously required at this level of detail.
- Acquisition Regulations: Newly mandates royalty reviews in federal contracting processes, expanding beyond current conflict-of-interest rules.
Potential Impacts
- On Government Agencies: Increases administrative workload for ethics offices, requiring new reporting, online publications, and conflict reviews; intelligence agencies face additional reporting to specialized committees, potentially straining resources but improving internal accountability.
- On Citizens: Enhances public access to information about potential influences on health and science policy, fostering trust in government decisions without broadly affecting daily life.
- On International Relations: Minimal direct impact, though greater transparency in U.S. science advising could indirectly influence global perceptions of impartiality in public health collaborations.
- On Employees and Contractors: Executive branch staff (especially in advisory roles) must disclose personal financial gains from inventions, which could deter participation or require divestment; contractors may face stricter scrutiny, possibly raising costs or limiting bidding opportunities.
Main Stakeholders Affected
- Executive Branch Employees: Particularly officers, special government employees, and members of public health/science advisory committees, who face new disclosure burdens.
- Federal Agencies: Including ethics offices, acquisition teams, and those overseeing advisory committees (e.g., HHS, DOD, DHS); required to implement reporting and publication.
- Congressional Committees: Gain enhanced access and oversight tools for monitoring ethics and conflicts.
- Contractors and Grantees: Subject to royalty-inclusive conflict reviews in federal awards.
- Public and Watchdog Groups: Benefit from increased transparency on government inventors' finances.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens ethics enforcement under existing disclosure laws (Ethics in Government Act) by piercing prior exemptions, potentially leading to more litigation over privacy vs. transparency; severability clause protects the Act's core from partial invalidation.
- Constitutional: Balances First Amendment interests in government transparency with privacy rights (e.g., redactions for personal data), avoiding broad speech restrictions; no direct challenges to separation of powers, as it empowers Congress's oversight role.
- Political: Promotes accountability in science and health policy-making, which could reduce perceptions of undue industry influence (e.g., in vaccine or biotech decisions); the 5-year sunset on committee expansions allows for periodic review, reflecting a targeted rather than permanent overhaul.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2025-09-17: Placed on Senate Legislative Calendar under General Orders. Calendar No. 165.
- 2025-09-17: Committee on Homeland Security and Governmental Affairs. Reported by Senator Paul with amendments. Without written report.
- 2025-09-17: Committee on Homeland Security and Governmental Affairs. Reported by Senator Paul with amendments. Without written report.
- 2025-07-30: Committee on Homeland Security and Governmental Affairs. Ordered to be reported without amendment favorably.
- 2025-03-05: Read twice and referred to the Committee on Homeland Security and Governmental Affairs.
- 2025-03-05: Introduced in Senate
Bill Versions
- Royalty Transparency Act — issued 2025-03-05 — PDF (14 pages)
- Royalty Transparency Act — issued 2025-09-17 — PDF (16 pages)